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Abstract
Background: The enzyme catalase is the main regu-
lator of hydrogen peroxide metabolism. Deficiency of
catalase may cause high concentrations of hydrogen
peroxide and increase the risk of the development of
pathologies for which oxidative stress is a contribut-
ing factor, for example, type 2 diabetes mellitus. Cat-
alase deficiency has been reported to be associated
with increased frequency of diabetes mellitus in a
cohort of patients in Hungary. In this cohort, the
majority of mutations in the catalase gene occur in
exon 2.
Methods: Type 2 diabetic patients (ns308) were
evaluated for mutations in intron 1 (81 bp), exon 2
(172 bp) and intron 2 (13 bp) of the catalase gene.
Screening for mutations utilized PCR single-strand
conformational polymorphism (SSCP) and PCR hete-
roduplex methods. Verification of detected mutations
was by nucleotide sequence analysis.
Results: A total of 11 catalase gene mutations were
detected in the 308 subjects (3.57%, p-0.001). Five of
the 11 were at two previously reported mutation sites:
exon 2 (79) G insertion and (138) GA insertion. Six of
the 11 were at five previously unreported catalase
mutation sites: intron 1 (60) G™T; intron 2 (7) G™A
and (5) G™C; exon 2 (96) T™A; and exon 2 (135) T™
A. The novel missense mutations on exon 2 (96 and
135) are associated with 59% and 48% decreased cat-
alase activity, respectively; the novel G™C mutation
on intron 2 (5) is associated with a 62% decrease in
catalase activity. Mutations detected on intron 1 (60)
and intron 2 (7) showed no change in catalase activity.
The G™C mutation on intron 2 (5) might be a splicing
mutation. The two missense mutations on exon 2 (96)
and (135) cause substitutions of amino acids 53
(Asp™Glu) and 66 (Glu™Cys) of the catalase protein.
These are close to amino acids that are important for
the binding of heme to catalase, 44 (Val) and 72–75
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(Arg, Val, Val, His). Changes in heme binding may be
responsible for the activity losses.
Conclusion: Mutations that cause decreased cata-
lase activity may contribute to susceptibility to inher-
ited type 2 diabetes mellitus. Exon 2 and neighboring
introns of the catalase gene may be minor hot spots
for type 2 diabetes mellitus susceptibility mutations.
Keywords: catalase gene; diabetes; nucleotide
sequence; oxidative stress; PCR heteroduplex; PCR-
SSCP
Introduction
Oxidative stress is associated with diabetes mellitus,
especially type 2 diabetes mellitus, which reportedly
involves elevated production of oxygen free radicals
(1). Abnormally high glucose concentrations, both
extra- and intra-cellular, increase oxidative stress by
enhancing the transformation of pro-oxidants to oxi-
dants. Reactive oxygen species, e.g., superoxide an-
ions and hydroxyl radicals, formed in this process
may contribute to both the development and later
complications of type 2 diabetes (2, 3). In type 2 dia-
betes, there is evidence that the stress-activated sig-
naling pathways lead to both insulin resistance and
impaired insulin secretion (4).
Natural defense mechanisms against oxidative
stress include the enzymes superoxide dismutase and
catalase. Superoxide dismutase converts the highly
reactive superoxide anion into less toxic hydrogen
peroxide. If sufficient catalase activity is not available
to metabolize the peroxide, high concentrations of the
hydrogen peroxide may lead to cell death (5), change
endothelial cell permeability (6), alter insulin secre-
tion (7), and impair insulin signaling (8).
The enzyme catalase (EC1.11.1.6) is the major reg-
ulator of the hydrogen peroxide concentration (9, 10).
A link between inherited catalase deficiency and
susceptibility to diabetes mellitus was first detected
in Hungary. In a cohort of 13 Hungarian families, 65
persons had catalase deficiency (two acatalasemic
homozygotes; 63 hypocatalasemic heterozygotes)
and 66 persons were normocatalasemic. Of those
with inherited catalase deficiency, eight (12.3%) were
diagnosed with diabetes (11). None of the 66 normo-
catalasemic family members had diabetes mellitus; in
contrast, both of the acatalasemic and six of the hypo-
catalesmic subjects had type 2 diabetes mellitus.
Both acatalasemic and two hypocatalasemic sub-
jects with diabetes had a GA insertion at position 138
of exon 2 in the catalase gene. Insertion of a G at
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position 79 of exon 2 was detected in one hypocata-
lasemic type 2 diabetes mellitus patient. These muta-
tions in exon 2 (at 79 or 138) may be part of the
descriptive link between catalase deficiency and dia-
betes for the majority (62.5%, i.e., 5 of 8) of the type
2 diabetic hypo/acatalasemic patients (12–15). Other
mutations were detected in the 59 promoter region of
the catalase gene, but appeared to be benign poly-
morphisms with no association with diabetes mellitus
(16).
Mean blood catalase activities were compared for
two groups: 137 diabetics (type 1, 45; type 2, 92)
and a non-diabetic population. The mean activities
were 94.4"19.2 MU/L for the diabetic group and
113.3"16.5 MU/L for the non-diabetic subjects. The
decrease was significant (p-0.005). None of these
subjects were known to be members of families with
inherited hypocatalasemia (17).
Blood catalase activity provides a general defense
against diffusible hydrogen peroxide, especially for
tissues with low catalase activities, for example pan-
creas and brain (9, 18, 19). Inherited or acquired cat-
alase deficiency may create chronic oxidative stress,
because abnormally low catalase activity will result in
chronic elevation of hydrogen peroxide concentra-
tions; the tissues most likely to be damaged are those
that normally have the least intracellular catalase
activity, e.g., the pancreas. High concentrations of
hydrogen peroxide may damage pancreatic b-cells
(11), mitochondrial electron transport (20), and influ-
ence homocysteine metabolism (21).
The evidence cited above suggests that in some
families there may be a link between type 2 diabetes
mellitus and catalase deficiency. There has been no
report on the frequency of catalase mutations in a
large cohort of type 2 diabetes mellitus patients.
The current study examined a large Hungarian
cohort of type 2 diabetes mellitus patients for catalase
gene mutations. The goals were (a) to determine the
frequency of the previously detected mutations asso-
ciated with diabetes mellitus at exon 2 (79 and 138),
which we call Hungarian type A and type B mutations;
and (b) to detect new mutations in the catalase gene,
which may also be associated with susceptibility
to diabetes. The hope is that the frequency and pat-
tern of mutations may suggest how catalase deficien-
cies are associated with increased risk of diabetes
mellitus.
Patients and methods
Type 2 diabetic patients (ns308) from throughout Hungary
were included in the study. Their ages ranged between 45
and 70 years, with a mean"SD of 58.4"6.5 years. The body
mass index was 28.5"1.9 kg/m2 for men and 27.3"2.1
kg/m2 for women. The upper limit of the reference range for
body mass index is 27 kg/m2 for men and 25 kg/m2 for wom-
en. The group included 128 males (41.6%) and 180 females
(58.4%). The criteria for diagnosis of diabetes were as
defined by the National Diabetes Data Group (22) (impaired
glucose tolerance test, increased hemoglobin A1c, glucos-
uria, anamnesis). Patients had stable diabetes as determined
by hemoglobin A1c tests. Exclusion criteria were stage III
symptomatic diabetic polyneuropathy, uncontrolled hyper-
tension, incipient renal insufficiency, history of cancer with
significant invasion or recurrence within 3 years, endocrine
disorders other than diabetes mellitus, peripheral neuro-
pathy, poor CYP2D6 metabolism, known other causes of sec-
ondary diabetes (e.g., pregnancy, surgery) and the use of
insulin therapy. There were no other selection criteria, e.g.,
severity of diabetes or time since diagnosis.
The age- and gender-matched control group included 120
healthy Hungarian subjects. Their ages ranged between 41
and 71 years (55.3"7.1 years). The exclusion criteria of this
group were any form of diabetes mellitus, inherited catalase
deficiency, anemia, and decreased (below the reference
range) blood catalase activity.
Genomic DNA was obtained from lymphocytes by stan-
dard methods (23, 24). PCR amplifications were performed
in a total volume of 10.5 mL containing 1 mL of genomic DNA
(0.2 mg/mL), 1 mL of each primer (10 mM), and 5 mL of RED-
Taq (Ready Mix) from Sigma-Aldrich (Budapest, Hungary).
Amplification cycles (30 cycles at 948C for 0.5 min, 628C for
0.5 min and 728C for 1 min) were carried out in a DNA Ther-
mal Cycler (Perkin Elmer Cetus TC 1, Norwalk, CT, USA) as
previously described (12, 14).
The primers for exon 2 (forward, 59-tgcaaagctatgtaccccgtg-
39; reverse, 59-acacagcacttacctgctcc-39) were as reported by
Kishimoto et al. (25) and purchased from Pharmacia Biotech
(Uppsala, Sweden). The 265 bp of the PCR product contained
80 bp of intron 1, 172 bp of exon 2, and 13 bp of intron 2.
For single-strand conformational polymorphism (SSCP)
analyses, 5 mL of PCR product, 5 mL of 99% formamide,
20 mM EDTA and 0.005% bromophenol blue weremixed and
heated at 968C for 6 min and rapidly cooled on ice. Electro-
phoresis was performed using a 6% polyacrylamide gel
(150=150=1.5 mm) running at 300 V for 5–6 h. DNA bands
were visualized by silver staining.
Our simple PCR heteroduplex screening method was used
to detect GA (12) and G insertions (14) in exon 2. This meth-
od showed four bands (wild-wild homoduplex at 268 bp,
mutant-mutant homoduplex at 270 bp, and two heterodu-
plex bands at 273 and 304 bp) for GA insertion and two
bands (homoduplexes at 268–270 bp, heteroduplex at
275 bp) for G insertion. The PCR product (2 mL) was heated
to 948C, cooled slowly, and then loaded onto 6% polyacryl-
amide gel (150=150=1.5 mm) running at 300 V for 3–4 h.
DNA bands were visualized by silver staining.
After screening-revealed mutations, nucleotide sequence
analyses were carried. PCR products were purified by aga-
rose gel electrophoresis. The separated DNA bands were
visualized by ethidium bromide staining. The stained bands
were cut out and their DNA was eluted in 100 mL of TE buffer
(10 mM Tris, 1 mM EDTA, pH 8.0).The eluted DNA was etha-
nol-precipitated, washed with 70% ethanol and dissolved in
10 mL of distilled water. These purified PCR products were
used for sequence analyses. The sequencing reactions
were carried out using a Taq Dye-Deoxy Termination Cycle
Sequencing Kit and a DNA Sequencer (Models 373 and 310,
Applied Biosystem, Foster City, CA, USA).
Blood catalase activity was determined using a spectro-
photometric method (26). Blood was taken with EDTA as
anticoagulant. A 20-mL aliquot of blood was diluted with
4.0 mL of 60 mmol/L sodium-potassium buffer (pH 7.4) and
the erythrocytes were lysed with 100 mL of a saponin solu-
tion (20 g/L). Then 30 mL of this hemolysate was immediately
incubated at 378C with 1.0 mL of substrate containing
65 mmol/mL hydrogen peroxide in the former buffer. After
60 s, the enzyme reaction was stopped by adding 1 mL of
32.4 mmol/L ammonium molybdate w(NH4)6Mo7O24Ø4H2Ox
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Table 1 Catalase gene (intron 1, 80 bp; exon 2, 172 bp; intron 2, 13 bp) mutations and blood catalase activities in 11 of 308
diabetic patients with type 2 diabetes mellitus.
Localization, Mutation Type Allelic Amino acid Catalase, % Reference
bp frequency, % MU/L
Intron 1 (60) G™T Substitution 0.32 – 106.3 93.8 New
90.3 79.7
Intron 2 (7) G™A Substitution 0.16 – 80.5 71.0 New
Intron 2 (5) G™C Substitution 0.16 – 70.3 62.0 New
Exon 2 (96) T™A Missense 0.16 53 Asp™Glu 60.3 53.2 New
Exon 2 (135) G™C Missense 0.16 6 Glu™Cys 58.9 52.1 New
Exon 2 (138) GA insertion Frameshift 0.48 69 Ile™Glu 52.3 46.2 (12)
60.3 63.2
61.2 54.0
Exon 2 (79) G insertion Frameshift 0.32 48 Pro™Ala 58.4 51.5 (14)
50.4 44.5
Figure 2 PCR-SSCP mutation screening of catalase exon 2
in diabetes mellitus. Lane 1, molecular mass marker; lanes
2–10, diabetic patients with SSCP polymorphism (2, 4–7) and
without SSCP polymorphism (3, 8–10).
Figure 1 PCR heteroduplex mutation screening of catalase
exon 2 in diabetes mellitus. A, wild-wild homoduplex; B1,
B2, wild-mutant heteroduplexes. Lane 1, heteroduplex con-
trol; lanes 2–5, diabetic patients with heteroduplex formation
(2) and without heteroduplexes (3–5).
Figure 4 Nucleotide sequence analysis of catalase exon 2
in a diabetic patient. The upper line shows the nucleotides
and the lower line their positions. The new mutation at posi-
tion 7 of intron 2 is a G™A substitution.
Figure 3 Nucleotide sequence analysis of catalase intron 2
in a diabetic patient. Upper line shows the nucleotides, lower
line, the nucleotide positions. The new mutation is a G™C
substitution at position 5 of intron 2.
and the yellow complex of molybdate and hydrogen perox-
ide was measured at 405 nm against blank. Enzyme activity
was defined as follows: 1 U of catalase decomposes 1 mmol
of hydrogen peroxide in 1 min under these conditions and
is related to 1 L of blood. Due to the very high turnover of
hydrogen peroxide by catalase and the high catalase content
in blood, the blood catalase activity is reported as MU/L. The
reference range for this method is 80.3–146.3 MU/L or mean
(SD)s113.3 (16.5) MU/L (26).
A x2 test was performed to assess the difference in allelic
frequencies of mutation between diabetic patients and heal-
thy controls.
The Student t-test was used to calculate the difference in
blood catalase activity between the diabetic patients with
mutations and healthy controls. The level for statistical sig-
nificance was set at p-0.005.
Results
PCR products from 92.5% (285 of 308) of the samples
from diabetic subjects revealed no mutations either
by PCR-SSCP or PCR heteroduplex analyses.
SSCP analyses revealed polymorphisms in samples
from 18 (5.8%) of the patients. Sequence analyses of
the PCR products identified two mutations (2 patients)
in intron 2, one mutation in intron 1 (2 patients), two
missense mutations (2 patients) in exon 2, and no
mutation sites in 12 of the 18 subjects.
Screening by the PCR heteroduplex method was
positive for samples from five patients (1.6% of 308).
Sequence analyses revealed a GA insertion in exon 2
(Hungarian type A) in three patients (;1%) and a G
insertion (Hungarian type B) in two patients (;0.6%),
as shown in Table 1.
The mutation screening tests (Figures 1 and 2) were
positive for 23 (7.5%) samples of 308 type 2 diabetes
mellitus patients. Nucleotide sequence analyses veri-
fied seven mutations in 11 patients. All of these 11
patients were heterozygotes for catalase deficiency.
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These mutations (Figures 3 and 4) were associated
with decreased (44.5–93.8%) blood catalase activity.
These data indicate that in 308 patients with type 2
diabetes mellitus, catalase gene mutations on exon 2,
intron 1 and intron 2 were detected in 3.57% (ns11)
of the patients. The allelic frequency of these muta-
tions was 1.78%.
Catalase activities for the 11 heterozygotes are
shown in Table 1. Mutations on intron 1 (60) caused
the least significant decrease in catalase activity
(93.8% and 79.7%) among these 11 heterozygotes,
with values of 106 and 90 MU/L compared to the pop-
ulation mean of 113.3"16.5 MU/L.
There was a significant difference (p-0.001) in alle-
lic frequencies of mutations between diabetic patients
(11 of 616) and healthy controls (0 of 240).
The mean and SD of blood catalase activity of dia-
betic patients with mutations (68.1"17.4 MU/L, ns11)
was significantly (p-0.001) lower compared to that
for all diabetic patients (90.5"16.9 MU/L, ns308). A
similar decrease (p-0.001) was found when diabetic
patients (90.5"16.9 MU/L, ns308) were compared to
the control subjects (103.8"17.5 MU/L, ns120).
Discussion
PCR-SSCP and PCR heteroduplex mutation screening
was useful for the detection of catalase gene muta-
tions in hereditary catalase deficiencies in Hungarian
patients (12–14, 16).
The PCR-SSCP method indicated mutations in 23
patients. Nucleotide sequence analyses revealed two
previously unreported mutations on intron 2 near the
exon/intron boundary (G™A at position 7 and G™C
at position 5). The subject with the nucleotide substi-
tution at position 5 with decreased catalase activity
(70.3 vs. 113.3 MU/L) may be associated with a defect
in exon splicing, as found for exons 4 (27) and 7 (13),
which were also associated with a decrease in cata-
lase activity.
The other patient with an intron 2 mutation (G™A
at position 7) had a blood catalase activity (81.5 MU/L)
at the low end of the reference range (80.3–146.3
MU/L).
The new G™C substitution at position 60 of intron
1 was detected in two unrelated patients. This muta-
tion did not cause a significant decrease in catalase
activity (100.3 and 90.9 MU/L). Due to the position of
this mutation and to the lack of a decrease in catalase
activity, we may suppose that this mutation might be
a benign polymorphism of the catalase gene.
The novel exon 2 mutations T™G (position 96) and
G™C (position 135) are missense mutations; the cor-
responding amino acid changes are asparagine™glu-
tamine (amino acid position 53) and glutamine™
cysteine (position 66). The amino-terminal domain of
catalase has 75 residues, which form an arm extend-
ing from a globular region of the enzyme. The arm
consists of two helices, both of which are involved in
intersubunit contacts. The second helix is essential for
binding of heme. Several amino acid residues (Val 44,
Arg 72, Val 73 and 74, His 75) are most important for
heme-protein binding.
The novel missense mutations (amino acids 53 and
66) are in the vicinity of these important amino acid
residues (28–30). Therefore, amino acid substitutions
in this region (exon 2 T™G at 96 and G™C at 135)
may decrease the catalase enzyme activity (60.3 and
58.9 MU/L, respectively vs. the reference range of
113.3"16.5 MU/L). Such a chronic decrease in blood
catalase activity may yield a lifelong increase in
hydrogen peroxide concentrations, which may con-
tribute to the development of type 2 diabetes mellitus
(11, 17, 20).
The PCR heteroduplex analyses detected hetero-
duplex formation characteristic of the Hungarian type
A (12) and B (14) catalase mutations. These are frame-
shift mutations with early stop codons that truncate
catalase proteins at 133 and 57 amino acids instead
of 517 amino acids. These results for diabetes melli-
tus patients not known to be members of families
with inherited catalase deficiency are consistent with
earlier reports. These two mutations were detected in
six of eight hypocatalasemic patients with type 2 dia-
betes mellitus. The frequency of diabetes mellitus in
patients with inherited catalase deficiency was signif-
icantly higher (12.7%) compared to the frequency of
1.8% in the general Hungarian population (11).
In the current study, catalase mutations on or near
exon 2 were detected in 3.57% of type 2 diabetes mel-
litus patients. The mutations detected included two
new benign polymorphisms with no significant
change in catalase activity (three patients), and muta-
tions with decreased catalase activity, including one
novel splicing mutation (one patient), two new mis-
sense mutations (two patients) and two known muta-
tions (five patients).
None of these new mutations were detected in the
120 non-diabetic control subjects.
Decreased catalase activity due to the mutations
may result in high steady-state concentrations
of hydrogen peroxide and oxidative stress. Peroxide
may damage pancreatic b-cells (11), mitochondrial
electron transport (20), homocysteine metabolism
(21), and insulin secretion and signaling (7, 8). These
factors may lead to insulin resistance and impaired
insulin secretion (4), although the mechanism respon-
sible for the development of this disease is not yet
known.
Our observations of catalase mutations on or near
exon 2 are consistent with a hypothesis that catalase
deficiency might be a minor factor that can contribute
to inherited susceptibility to type 2 diabetes mellitus.
This region of the catalase gene might be a hot spot
for mutations that contribute to the pathogenesis of
type 2 diabetes mellitus.
In conclusion, the new mutations on exon 2 (mis-
sense mutations at positions 96 and 135) and intron
2 (substitution at position 5), together with the previ-
ously identified exon 2 mutations (frameshift at
positions 135 and 79) might be involved in the patho-
mechanism of diabetes mellitus. These catalase
mutations might be regarded as risk factors for type
2 diabetes mellitus.
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